Mini Review Open Access
Volume 4 | Issue 1 | DOI: https://doi.org/10.33696/AIDS.4.027
Known and New Routes to Neutralize HIV-1 with Camelid Single Chain Antibody Fragments
C. Theo Verrips1,*, Gerben ten Hag2, Ursula Dietrich3, Harold Marcotte4
- 1Retired Unilever, QVQ Holding,b.v. and Utrecht University, The Netherlands
- 2Department of Applied Stem Cell Technologies, TechMed Centre, University of Twente, Enschede, the Netherlands
- 3Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany
- 4Department of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Sweden
Corresponding Author
C. Theo Verrips, theo.verrips@outlook.com
Received Date: January 12, 2022
Accepted Date: April 20, 2022
Verrips T, ten Hag G, Dietrich U, Marcotte H. Known and New Routes to Neutralize HIV-1 with Camelid Single Chain Antibody Fragments. J AIDS HIV Treat. 2022;4(1):14-21.
Copyright: © 2022 Verrips T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
CCR5 Inhibitors and HIV-1 Infection
Cellular components are attractive targets for antiviral therapy because they do not mutate as readily as do viral proteins do [1-3]. The identification of CCR5 as an HIV-1 coreceptor [4-7], facilitated by the discovery of the antiviral activities of CCR5 ligand ?-chemokines [8], resulted in the development of new viral entry inhibitors to block CCR5 binding, including both- small molecules and CCR5 antibodies
Recent Progress in Preclinical HIV-1 Vaccine Research
Since isolation in humans in 1983 [1,2], HIV-1 has developed into a global pandemic. But an effective HIV-1 vaccine has not been succeeded despite multiple human vaccine trials performed [3,4]. Challenges to an effective vaccine arise from intrinsic virological and immunological features of HIV-1 [3-8].
Anti-HIV-1 Activity of Crocodylus mindorensis (Philippine Crocodile) Serum in Cell-free and Cell-associated Virus Interactions to Human Peripheral Blood Mononuclear Cells
Highly-Active Antiretroviral Therapy (HAART) is the recommended treatment and management strategy for HIV infection. Although the existing antiretroviral drugs are indispensably significant in improving the quality and extending the lives of HIV/ AIDS individuals, the drugs still have many limitations including development of resistance, production of toxicity, and their limited availability.
Assessment of Attitudes toward HIV and AIDS among Undergraduate Students at a Historically Black University
HIV is no longer only a public health challenge, but also a global threat with a devastating negative impact that has claimed over 35 million lives globally. In 2017, about 36.9 million people live with HIV, and 1.8 million people becoming newly infected with the disease globally [1].
HIV-1 Treatment Failure among Population Taking Antiretroviral Therapy in Ethiopia
For more than 35 years, the world has grappled with an AIDS epidemic that has claimed an estimated 35.0 million [28.9 million-41.5 million] lives and at its peak threatened global stability and security.